期刊文献+

干扰素脂质体的制备与质量控制 被引量:2

Preparation and Quality Control of Interferon Liposome
下载PDF
导出
摘要 目的制备干扰素脂质体并建立其质量控制方法。方法采用逆相蒸发法制备干扰素脂质体。通过电镜测定其粒径,采用细胞病变抑制法测定包封率。结果干扰素脂质体透射电镜下观察为圆形,平均粒径为285.6 nm,包封率为63.52%;有机物残留量低于2005年版《中国药典(二部)》规定的标准;在2~8℃下保存6个月,总活性基本不变。结论该制剂制备方法可行,所得成品稳定性好,且所建立的质量控制方法简便、可靠,适用于干扰素脂质体的大生产。 Objective To prepare the interferon liposome and to establish its quality control.Methods The interferon liposome was prepared by the reverse phase evaporation method.The particle size was detected by using electron microscope and the envelope rate was tested by the cytopathic-effect inhibition assay.Results The interferon liposome was in a form of round particle under transmission electron mi-croscope.The mean diameter was 285.6 nm and the envelope rate was 63.52%.The residual organic content was less than the standard described in the Chinese Pharmacopoeia(edition 2005,volume Ⅱ).After storage at 2-8 ℃ for 6 months,the total activity of interferon showed no significant change.Conclusion This preparation method is practicable and suitable for mass production;the finished preparation is stable in quality and the established quality control method is simple and reliable.
出处 《中国药业》 CAS 2010年第19期37-38,共2页 China Pharmaceuticals
关键词 干扰素 脂质体 制备 质量控制 interferon liposome preparation quality control
  • 相关文献

参考文献1

二级参考文献13

  • 1Fomenko L, Sirota N, Iavin V, et al. Interferon alpha reduces the level of radiation- induced micronuclei in mouse bone marrow cells[J]. Arch Immunol Ther Exp (Warsz), 1997, 45 (5 - 6): 475 - 478.
  • 2Coradini D, Pellizzaro C, Biffi A, et al. Effect of Liposome -encapsulated alpha - or beta - interfedron on breast cancer cell lines[J]. Aoticancer Res, 1998 Jan -Feb, 18(IA): 177-182.
  • 3Van Slooten ML, Kircheis R, Koppenhagen FJ, et al. Liposmnes as cytokine-supplement in tumor cell-based vaccines[J].lnt J Pharm,1999 Jun1O, 183(1):33-36.
  • 4Takeuchi M, Tredget EE, Scott PG, et al. The antifibrogenic effcts of liposome-encapsulated IFN-alpha2h cream on skin wounds[J].J lnterferon Cylokine Res, 1999 Dec, 19(12): 1413-1419.
  • 5Foldvari M, Baca-Estrada ME, He Z, et al. Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha[J] .Biotechnol Appl Biochem, 1999 Oct, 30(Pt 2):129 - 137.
  • 6Everlien H, Hockertz S. Combined ]iposoma[ immuno-and chemotherapy of visceral leishmaniasis[ J ]. Arzneimittelforschung, 1999 Nov, 49 ( 11 ):954 - 961.
  • 7Marguglio A, Hoyoux C, Dresse MF, et al. leishmaniose viscerale chroniqueau coursd' une ehimiotherapie pour osteosarcome metastatique [J]. Arch Pediatr, 1998 Mar, 5(3): 285 -288.
  • 8Jackel A, Deichmann M, Waldmann V, et al. Regression of metastatic angiosarcoma ot the skin after systemic treatment with liposome- encapsulated doxorubicin and interferon - alpha[ In Process Citation] [J ].Br J Dermatol, 1999 Jun, 140(6): 1187-1188.
  • 9Saravolae EG, Kournikakis B, Gorton L, et al. Effect of liposome -encapsulation on immunomodulating and anliviral activities of interferon - gamma 1 [J]. Antiviral Res, 1996 Mar, 29(2 - 3): 199 - 207.
  • 10Zolin VV, Kolokol tsov AA, Agafonova OA, et al. Design of human liposomal recombinant alpha2- inlerferon- eontaining preparation[J].Vestn Ross Akad Med Nauk, 1999, (12):18-22.

共引文献3

同被引文献28

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部